The Relationships Between the Noradrenergic, Opioid and Pain System

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01851486

Enrollment

Registered

2013-05-10

Start date

2013-01-31

Completion date

2016-09-30

Last updated

2017-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Experimental Pain Perception

Brief summary

The role of alpha2 receptor agonist on pain perception and modulation will be examined. In addition whether this is mediated through the opioid system will be examined. Pain perception and modulation will be examined before and after administration of Clonidine or placebo together with Naloxone or saline.

Interventions

DRUGClonidine

Clonidine 0.15 mg

DRUGNaloxone

naloxone 0.15 mg/kg

DRUGplacebo

OTHERsaline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers * Age 18-40 * No chronic disease

Exclusion criteria

* Subjects who suffer from chronic pain / pain syndrome * use of anti-depressant or anti-psychotic drugs * suffering from cardiovascular disease * breast feeding

Design outcomes

Primary

Measure	Time frame	Description
The changes in pain responses after administration of alpha 2 agonist and mu receptor antagonist	2 years	The change in pain perception (pain thresholds and pain ratings of suprathresholds stimuli) and in the excitatory and inhibitory pain modulation responses (assessed by the temporal summation and conditioned pain modulation paradigms) will be examined before and after administration of alpha 2 agonist with and without mu receptor antagonist

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026